MET and glioblastoma: separated IDH-mutant glioblastoma into G-CIMP-high group and G-CIMP-low group without CDKN2A and MET alteration with favorable and comparable overall survival, while G-CIMP-low group with CDKN2A and/or MET alteration showed significantly shorter overall survival in univariate and multivariate analysis (290).